

# Corporate Profile

The core business of Jiwa Bio-Pharm Holdings Limited (the "Company") and its subsidiaries (collectively the "Group") includes research and production of pharmaceutical products in China and trading and distribution of pharmaceutical products for European pharmaceutical companies. In recent years, the Group has also started to produce prescription Chinese medicines and Chinese health-care products, and will soon begin production of pharmaceutical bulk materials. The Group planned to develop the Southeast Asian, European and US markets in stages.

At the beginning of its establishment, the Group was principally engaged in the production and trading of anti-infectious and other specialized pharmaceutical products. In recent years, the Group has made strategic adjustments to its product mix and focused on developing

drugs for five therapeutic categories in response to changing market demands and state policy changes in the PRC. In addition to the existing anti-infectious, gastro-intestinal and musculo-skeletal drugs, the group begun to develop cerebro-cardiovascular, anti-depressant and psychiatric disorder drugs. The contribution of the later two categories of drugs to the turnover of the Group is expected to increase gradually in the future to mitigate reliance on the anti-infectious drugs.

The Group dedicates itself to the overall development of its pharmaceutical business from research and development to production and distribution of its products. This is to ensure the reliability of product quality, cost efficiency in production and first-hand information on markets.

## CORPORATE STRUCTURE

